These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33783343)

  • 61. [Ezetimibe in clinical practice: from laboratory investigations to the IMPROVE-IT trial results].
    Borghi C; Filardi PP
    G Ital Cardiol (Rome); 2015; 16(7-8 Suppl 1):3S-14S. PubMed ID: 26442834
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Consensus statement of professional associations on prescribing of PCSK9-inhibitors.
    Češka R; Táborský M; Vrablík M
    Vnitr Lek; 2019; 64(12):1131-1136. PubMed ID: 30704246
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Quantitative evaluation of statin effectiveness versus intolerance and strategies for management of intolerance.
    Soran H; France M; Adam S; Iqbal Z; Ho JH; Durrington PN
    Atherosclerosis; 2020 Aug; 306():33-40. PubMed ID: 32683135
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Statins and PCSK9 inhibitors: A new lipid-lowering therapy.
    Gallego-Colon E; Daum A; Yosefy C
    Eur J Pharmacol; 2020 Jul; 878():173114. PubMed ID: 32302598
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe.
    Khunti K; Danese MD; Kutikova L; Catterick D; Sorio-Vilela F; Gleeson M; Kondapally Seshasai SR; Brownrigg J; Ray KK
    JAMA Netw Open; 2018 Dec; 1(8):e185554. PubMed ID: 30646277
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease.
    Toth PP; Dwyer JP; Cannon CP; Colhoun HM; Rader DJ; Upadhyay A; Louie MJ; Koren A; Letierce A; Mandel J; Banach M
    Kidney Int; 2018 Jun; 93(6):1397-1408. PubMed ID: 29526502
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States.
    Gandra SR; Villa G; Fonarow GC; Lothgren M; Lindgren P; Somaratne R; van Hout B
    Clin Cardiol; 2016 Jun; 39(6):313-20. PubMed ID: 27092712
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events.
    Lee S; Cannon CP
    Curr Cardiol Rep; 2018 May; 20(7):55. PubMed ID: 29802475
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance.
    Koskinas K; Wilhelm M; Windecker S
    Swiss Med Wkly; 2016; 146():w14333. PubMed ID: 27400448
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
    Cannon CP; Blazing MA; Giugliano RP; McCagg A; White JA; Theroux P; Darius H; Lewis BS; Ophuis TO; Jukema JW; De Ferrari GM; Ruzyllo W; De Lucca P; Im K; Bohula EA; Reist C; Wiviott SD; Tershakovec AM; Musliner TA; Braunwald E; Califf RM;
    N Engl J Med; 2015 Jun; 372(25):2387-97. PubMed ID: 26039521
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial.
    Moriarty PM; Jacobson TA; Bruckert E; Thompson PD; Guyton JR; Baccara-Dinet MT; Gipe D
    J Clin Lipidol; 2014; 8(6):554-561. PubMed ID: 25499937
    [TBL] [Abstract][Full Text] [Related]  

  • 72. An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: Barriers to be overcome.
    Drexel H; Coats AJS; Spoletini I; Bilato C; Mollace V; Perrone Filardi P; Rosano GMC
    Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):115-121. PubMed ID: 31873726
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidaemias.
    Wierzbicki AS; Doherty E; Lumb PJ; Chik G; Crook MA
    Curr Med Res Opin; 2005 Mar; 21(3):333-8. PubMed ID: 15811200
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease.
    Toth PP; Foody JM; Tomassini JE; Sajjan SG; Ramey DR; Neff DR; Tershakovec AM; Hu XH; Tunceli K
    J Clin Lipidol; 2014; 8(1):107-16. PubMed ID: 24528691
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
    Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Passino C; Gabutti A; Pasanisi EM; Petersen C; Valleggi A; Todiere G; Barison A; Giannoni A; Panchetti L; Becherini F; Pianelli M; Luciani R; Sampietro T
    Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Suggested clinical approach for the diagnosis and management of 'statin intolerance' with an emphasis on muscle-related side-effects.
    Sivashanmugarajah A; Fulcher J; Sullivan D; Elam M; Jenkins A; Keech A
    Intern Med J; 2019 Sep; 49(9):1081-1091. PubMed ID: 31507054
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Is it appropriate to make statins available over the counter? The argument against the appropriateness of over-the-counter statins.
    Barter PJ; Rye KA
    Circulation; 2006 Sep; 114(12):1315-20; discussion 1320. PubMed ID: 16982953
    [No Abstract]   [Full Text] [Related]  

  • 78. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Cardiovascular event rates and trajectories of LDL-cholesterol levels and lipid-lowering therapy in patients with atherosclerotic cardiovascular disease: A population-based cohort study.
    Sundbøll J; Larsen AP; Veres K; Adelborg K; Sørensen HT
    Thromb Res; 2019 Nov; 183():124-130. PubMed ID: 31677592
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
    Robinson JG; Farnier M; Krempf M; Bergeron J; Luc G; Averna M; Stroes ES; Langslet G; Raal FJ; El Shahawy M; Koren MJ; Lepor NE; Lorenzato C; Pordy R; Chaudhari U; Kastelein JJ;
    N Engl J Med; 2015 Apr; 372(16):1489-99. PubMed ID: 25773378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.